424B4424B4
Sep 3, 2026Final prospectus0001193125-26-381149
All companies
Trade Aptevo Therapeutics Inc424B4Sep 3, 2026
AP
Aptevo Therapeutics Inc
APVOPublicArchived
Public / ArchivedUnited States(Nasdaq)Best valuation $3.14M1 market
Public listing
Listed· Nasdaq· Listing market: United StatesListing date
Not available
Offer price
Not available
Shares offered
Not available
Offering proceeds
Not available
Sources: sec-edgar, sec-harvest, nasdaq
IPO Calendar · NasdaqIPO
APVOPrice
$1.74
24h
+1.75%
Valuation
$3.14M
24h volume
$474.97K
Type
IPO
Trade Aptevo Therapeutics IncNow trading publicly. Buy via a broker — opens in a new tab.
IPO Calendar · updated 1h ago
Aptevo Therapeutics Inc IPO public float & lock-up
Public float and locked shares extracted from Aptevo Therapeutics Inc's SEC prospectus. Shares shown are eligible to trade — lock-up expiry does not mean holders have sold or will sell.
Total shares (FD)
1.81M
Public float
—
Locked
—
IPO raise
—
Next unlock
—
Needs review: Could not extract a detailed lock-up release schedule.
Financials
UnprofitableFrom SEC filings, latest FY ending Dec 31, 2022 · CIK 0001671584.
Revenue · -74.67% YoY
$3.11M
Net income
-$25.97M
Gross margin
—
Cash
$21.62M
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | — | — | — | $3.11M | $12.29M |
| Operating income | -$26.31M | -$24.6M | -$28.88M | -$28.64M | -$21.4M |
| Net income | -$25.97M | -$24.13M | -$17.41M | $8.03M | -$28.46M |
| R&D expense | $14.54M | $14.38M | $17.11M | $17.88M | $18.99M |
| Cash & equivalents | $21.62M | $8.71M | $16.9M | $22.64M | $45.04M |
| Total assets | $27.19M | $15.59M | $24.84M | $34.22M | $56.6M |
| Total liabilities | $9.81M | $10.84M | $12.62M | $16.24M | $55.39M |
| Shareholders' equity | $17.38M | $4.76M | $12.22M | $17.97M | $1.22M |
SEC IPO filings
Final prospectusEDGAR filings resolved from APVO / CIK 0001671584.
Sep 2, 2026Effective9999999995-26-002871
S-1S-1
Aug 21, 2026Filed0001193125-26-361103
Jan 30, 2026Effective9999999995-26-000430
424B4424B4
Jan 30, 2026Final prospectus0001193125-26-032011
CORRESPfilename1.htm
Jan 29, 2026SEC correspondence0001193125-26-029443
UPLOADfilename1.pdf
Jan 29, 2026SEC correspondence0000000000-26-001091
S-1S-1
Jan 28, 2026Filed0001193125-26-027200
Nov 25, 2025Effective9999999995-25-003381
424B4424B4
Nov 25, 2025Final prospectus0001193125-25-297513
CORRESPfilename1.htm
Nov 24, 2025SEC correspondence0001193125-25-293460
S-1S-1
Oct 1, 2025Filed0001193125-25-226825
Aptevo Therapeutics Inc IPO — frequently asked questions
- When did Aptevo Therapeutics Inc go public?
- Aptevo Therapeutics Inc has already gone public and now trades publicly on Nasdaq under the ticker APVO.
- Can I buy Aptevo Therapeutics Inc stock?
- Yes — Aptevo Therapeutics Inc is publicly traded on Nasdaq as APVO. You can follow its live price, valuation and post-IPO performance above.
- What is Aptevo Therapeutics Inc's valuation?
- Aptevo Therapeutics Inc's most recent valuation tracked here is $3.14M, derived from live market prices.